[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lille Catholic University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":356},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,50,80,111,139,169,198,224,253,278,305,333],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100522499","early-breast-growth-in-girls-aged-6-to-8-years-in-the-current-environmental-context-100522499",false,"NCT06083415","Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context","Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context: Clinical and Biological Parameters, Level of Impregnation With Endocrine Disruptors and Evaluation of the Impact of Environmental Health Measures","PENELOPE","For patients:\n\nInclusion Criteria:\n\n* Girls aged 6 to 8 years\n* Presenting a breast development (isolated or not)\n* Undergoing scheduled pediatric day hospital care (HDJ)\n* Who agree to participate in the study\n* Whose parents agree to their child's participation in the study\n* French speaking\n* Whose parents speak French\n* Affiliated to social security\n\nExclusion Criteria:\n\n* Organic brain causes of precocious puberty: History of neurocerebral disease (malformations, developmental abnormalities)\n* Organic causes of precocious puberty: Mac Cune Albright syndrome, ovarian cyst or tumor and adrenal hyperplasia\n* History of chemotherapy or radiation therapy\n* Presenting with a communication disorder\n* Pregnancy\n* Persons under protective measures\n* Persons deprived of liberty for judicial or administrative reasons\n\nFor controls:\n\nInclusion Criteria:\n\n* Girls aged 6 to 8\n* Tanner stage 1: Absence of breasts and hairiness\n* Coming for routine consultation in the pediatric HDJ at Saint-Vincent-de-Paul hospital, or at the BLM practice in Lambersart, or to radiology for an MRI for another medical other medical reason\n* Agree to participate in the study\n* Whose parents agree to their child's participation in the the study\n* French-speaking\n* Whose parents speak French\n* Affiliated with social security\n\nExclusion Criteria:\n\n* Signs of puberty (Tanner stages 2, 3, 4 and 5 for breast development) breast development)\n* Previous chemotherapy or radiotherapy\n* Presenting a communication disorder\n* Pregnant women\n* Persons under protective supervision\n* Persons deprived of their liberty for judicial or administrative reasons","FEMALE","6 Years","8 Years",{"count":21,"type":22},62,"ESTIMATED","INTERVENTIONAL",[25],"NA","Various studies show an increase in the number of cases of early puberty in girls with breast development with a variable clinical presentation and evolution. This increasing phenomenon concerns girls between 6 and 8 years old. In a large number of cases, from 70 to 95% depending on the series, no medical cause is found and environmental factors are suspected to be involved.\n\nDescriptive studies of these patients are scarce and not always provide an overview of all the parameters in line with the concept of the exposome.\n\nThe PENELOPE clinical trial will allow to analyze a large number of parameters, including the adipose tissue, its metabolism, the endocrine disruptors, and the epigenetic modifications, and to study the impact of environmental health measures in the evolution of these parameters.\n\nThe data from the analyses of the endocrine disruptors of the patients will be explored in parallel in experimental models (amphibians, murine, cellular) in order to test potential mechanistic hypotheses.",[28,29,30],"Puberty, Precocious","Breast","Environmental Exposure",[32,33,34,35,36],"Early puberty","Endocrine disruptors","Girls","Breast growth","Environmental Health Measure","RECRUITING","2026-03-16",{"date":40,"type":41},"2026-03-17","ACTUAL",{"date":43,"type":41},"2023-05-15",{"date":45,"type":22},"2027-05-15",{"name":47,"class":48},"Lille Catholic University","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100629396","serious-game-rehabilitation-and-brain-plasticity-in-ms-100629396","NCT07474129","Serious Game Rehabilitation and Brain Plasticity in MS","Brain Reorganization After Serious Game -Based Cognitive Rehabilitation in Multiple Sclerosis","REVEILLE","Inclusion Criteria:\n\n* People with relapsing-remitting or progressive MS defined according to the 2010 revised McDonald criteria \\[56\\]\n* Cognitive complaints and deficits in at least one score on the initial neuropsychological examination (\\\u003C5th percentile of the reference group)\n* Aged between ≥ 18 and ≤ 65 years\n* No defined relapse for at least 6 weeks\n* At least 4 weeks since a corticosteroid bolus\n* Patient with an internet connection\n* Patient covered by social security\n* Signed informed consent\n\nExclusion Criteria:\n\n* Claustrophobia preventing MRI;\n* Contraindication to MRI;\n* Wearing fixed dental braces;\n* Unable to receive oral and written information;\n* Unable to use the software (due in particular to motor and\u002For sensory difficulties);\n* Neurological or psychiatric comorbidity, other than MS and anxiety-depression syndrome,\n* Patient with severe anxiety-depression syndrome (BDI-FS \\> 10),\n* Pregnant or breastfeeding women\n* Taking neuroleptic treatment\n* Person under guardianship or curatorship\n* Person deprived of liberty","ALL","18 Years","65 Years",{"count":62,"type":22},40,[25],"This prospective, interventional, longitudinal, multicentre study aims to evaluate the impact of the \"Serious game\", an innovative cognitive remediation tool on brain reorganization in Multiple sclerosis patients, using functional Magnetic resonance imaging (MRI). The serious game is a tool combining the motivational mechanisms of video games with cognitive remediation techniques.",[66],"Multiple Sclerosis (MS)",[68,69,70,71],"Multiple sclerosis","Serious Game","Cognitive rehabilitation","Magnetic resonance imaging","NOT_YET_RECRUITING","2026-03-11",{"date":38,"type":41},{"date":76,"type":22},"2026-06",{"date":78,"type":22},"2030-03",{"name":47,"class":48},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":58,"minAge":59,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100619339","landscape-of-gout-in-french-polynesia-100619339","NCT07343336","Landscape of Gout in French Polynesia.","FENUA-METABOGOUT : Genetic Landscape of Gout, Inflammation and Metabolic Diseases in French Polynesia.","METABOGOUT","Inclusion Criteria:\n\nAll participants:\n\n* Age between 18 and 75 years old inclusive\n* Signature of informed consent\n* Fasting for the collection of biological samples\n* Declared Polynesian ancestry\n* Affiliated to a social security scheme\n\nGeneral population group :\n\n* Not having participated to the 2021 TOPATA study\n* Visiting a general practitioner (for whatever reason)\n\nGout Group :\n\n* Managed at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard.\n\nTophaceous gout sub-group:\n\n* Present with tophaceous gout.\n\nGout crisis subgroup:\n\n* Be within 48 hours of the onset of a gout attack\n* Agree to return 1 week after inclusion for the second blood and urine sample.\n\n  2021 follow-up group:\n* To have been included in the TOPATA study in 2021\n* Have taken the genetic and biological samples that generated the genetic and serum urate data for the 2021 study\n* Have hyperuricaemia without signs of gout OR without hyperuricaemia or gout at the time of inclusion in TOPATA\n\nExclusion Criteria:\n\nAll participants :\n\n* Refusal or inability to understand or give consent\n* Physical inability to follow and respect the protocol\n* 1st degree relative\\*,\n* Person under guardianship or trusteeship\n* Pregnant or breast-feeding woman\n\n  \\* If several relatives from the same household are eligible to participate, only one person may be included in the study. The choice is left to the discretion of the investigator or the first person met. However, both members of a couple (e.g. husband and wife) may participate.\n* General population group :\n* Unable to return for sampling if required.\n* Gout group :\n* Person wearing a knee prosthesis\n* People suffering from other inflammatory rheumatic diseases",true,"75 Years",{"count":91,"type":22},2750,"OBSERVATIONAL","The aim of this research is to characterise the genetic and molecular landscape of gout, inflammation and metabolic diseases, as well as the associated molecular, anthropomorphic and pathological characteristics.",[95,96,97],"Gout Disease","Metabolic Diseases","Inflammation",[99,100,101],"Gout disease","metabolic disease","inflammation","2026-01-06",{"date":104,"type":41},"2026-01-15",{"date":106,"type":41},"2025-09-02",{"date":108,"type":22},"2027-09",{"name":47,"class":48},6,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":110},"100415814","remediation-program-via-a-serious-game-for-the-cognitive-functions-of-multiple-sclerosis-patients-100415814","NCT04694534","Remediation Program Via a \"Serious Game\" for the Cognitive Functions of Multiple Sclerosis Patients","e-SEP Cognition: Effectiveness of a Remediation Program Via a \"Serious Game\" on the Cognitive Functions of Multiple Sclerosis Patients: Controlled, Randomized, Multicentric Trial","E-SEP","Inclusion Criteria:\n\n* Relapsing-remitting or progressive multiple sclerosis people defined according to Mc Donald's criteria revised in 2005\n* Age between ≥ 18 and ≤ 65 years old\n* Cognitive complaint, with at least one deficient score at the initial neuropsychological examination (\\\u003C5th percentile of the reference group), one of the scores of which concerns at least one BICAMS test\n* Have not had a definite relapse for at least 6 weeks\n* Be at least 4 weeks away from a corticosteroid bolus\n* Lack of neuroleptic treatment\n* Patient with an Internet connection\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severe cognitive deficit defined by obtaining a deficit score in more than six cognitive processes at the initial neuropsychological assessment.\n* Neuropsychological care\n* Inability to receive oral and written information\n* Inability to use the software (due in particular to motor and \u002F or sensory difficulties),\n* Neurological or psychiatric comorbidity, other than MS and anxiodepressive syndrome\n* Patient with severe anxiodepressive syndrome (BDI\\> 27)\n* Participation in an interventional study on cognitive functions\n* Patient under legal protection, guardianship or curatorship\n* Pregnant or breastfeeding women",{"count":120,"type":22},150,[25],"The main goal of this study is to assess the effectiveness of a cognitive remediation program based on a \"serious game\" on the information processing speed evolution and the process of learning via episodic memory in multiple sclerosis patients.",[124,125,126],"Multiple Sclerosis","Memory","Learning",[68,128,129,130],"Serious game","Episodic memory learning capacities","Information processing speed capacities","2025-09-03",{"date":133,"type":41},"2025-09-04",{"date":135,"type":41},"2021-10-08",{"date":137,"type":22},"2027-03-01",{"name":47,"class":48},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":58,"minAge":60,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100593389","calcium-pyrophosphate-deposition-cppd-disease-100593389","NCT07005804","Calcium Pyrophosphate Deposition (CPPD) Disease","Calcium Pyrophosphate Deposition (CPPD) Disease : Clinical and Paraclinical Profile, Gene Expression and Metabolomics of the Acute and Chronic Clinical Phenotype","PYC-OMIC","Inclusion Criteria - Acute forms of CPPD: retrospective part of the study\n\n* Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD\n\nInclusion Criteria - Chronical forms of CPPD : prospective part of the study\n\n* Patients affiliated to the French social security system\n* Age ≥ 65 years\n* Diagnosis of chronic CPPD (recurrent acute or persistent arthritis), meeting ACR\u002FEULAR 2023,11 classification criteria after evaluation by a rheumatologist in the rheumatology department\n* Progression of CPPD rheumatism for at least 3 months and still active CPPD rheumatism, defined by a visual analogue scale (VAS) of disease activity ≥ 40 and\u002For presentation of at least 1 crisis over the last 3 months\n* Glomerular Filtration Rate (GFR) in Chronic Kidney Disease Epidemiology (CKD EPI Collaboration) ≥ 30ml\u002Fmin\u002F1.73m2\n* Minimum time between the last intake of a crisis treatment and inclusion in the study, depending on their half-life, in order to not interfere with the results of the omics analyses: 2 weeks (Nonsteroidal Anti-Inflammatory Drugs Per Os (PO) or Intramuscular (IM) or Intravenous (IV); corticosteroids PO or IV; colchicine PO; anakinra Subcutaneous (SC), 1 month (methotrexate PO, tocilizumab SC), 3 months (canakinumab SC, tocilizumab IV)\n* Signed written consent for study participation\n\nExclusion Criteria - Acute forms of CPPD:\n\n* Missing data concerning transcriptomic and metabolomic analyses.\n* Opposition\n\nExclusion Criteria - For chronic forms of CPPD:\n\n* History of gout or presence of monosodium urate (MSU) crystals on joint fluid,\n* Cognitive decline (confusion and neurodegenerative diseases)\n* Inability to provide informed consent and disease VAS\n* Patient under guardianship or curatorship",{"count":148,"type":22},137,[25],"The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD.\n\nThe hypotheses are as follows :\n\n* It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one\n* It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation.\n\nThe management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.",[152,153],"Calcium Pyrophosphate Deposition Disease","Rheumatic Diseases",[155,156,157,158,159],"Calcium pyrophosphate deposition disease","gene expression","acute clinical phenotype","chronic clinical phenotype","metabolic expression","2025-05-26",{"date":162,"type":41},"2025-06-05",{"date":164,"type":22},"2025-10",{"date":166,"type":22},"2027-11",{"name":47,"class":48},1,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":58,"minAge":4,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":168},"100564885","observatory-of-the-lille-paediatric-allergy-unit-100564885","NCT06634992","Observatory of the Lille Paediatric Allergy Unit","Paediatric Observatory of Oral Food Tolerance Induction in the Allergy Department of the Saint-Vincent de Paul Hospital in Lille","PAUL","Inclusion criteria:\n\n* patient under 15 years and 9 months,\n* positive diagnosis of food allergy (positive food challenge test or \"highly probable allergy\", defined by a convincing history, a positive prick test and IgE \\> 0.35 kUA\u002FL),\n* eligible for oral food challenge\n* accepting the following allergens : hazelnut, walnut, pistachio, cashew, peanut, cow's milk, wheat, egg, sesame, celery, fenugreek, pea, lentils or others\n\nExclusion criteria:\n\n* Opposition\n* Already received oral challenge for the same allergen.","16 Years",{"count":179,"type":22},1000,"The goal of this study is to set up a paediatric observatory within the allergology department of The saint Vincent Hospital, Lille. The study aims to:\n\n• Collect exhaustive prospective data from patients eligible for oral immunotherapy.\n\nThis prospective observatory will enable statistical analyses to be carried out on common food allergens such as hazelnut, cashew nut, pistachio and others.",[182,183,184],"Child Allergy","IgE-Mediated Allergic Process","Food Allergy",[186,187,188,189],"Food allergy","Food challenge test","IgE-Mediated","Observatory","2024-10-08",{"date":192,"type":41},"2024-10-10",{"date":194,"type":41},"2022-01-01",{"date":196,"type":22},"2024-12-31",{"name":47,"class":48},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":49},"100535941","gait-initiation-and-transition-from-double-to-single-support-in-patients-with-unilateral-primary-coxarthrosis-100535941","NCT06258369","Gait Initiation and Transition From Double to Single Support in Patients With Unilateral Primary Coxarthrosis","Gait Initiation and Transition From Double to Single Support in Patients With Unilateral Primary Coxarthrosis Who Have Not Undergone Surgery and Before\u002FAfter Arthroplasty","COXAM","Inclusion Criteria:\n\n* Men or women aged 18 and over\n* With primary coxarthrosis (any stage)\n* Consulting in the orthopedic departments of participating centers in anticipation of hip surgery (PTH\u002FRTH), or for advice only.\n* Written consent signed by the patient\n* Affiliation with a social security scheme\n\nExclusion Criteria:\n\n* Disabling orthopaedic conditions:\n\nSymptomatic contralateral hip\u002Fknee disease Symptomatic gonarthrosis or homolateral total knee prosthesis History of surgery on the affected hip History of fracture of the lower limb in the past year History of lower limb sprain in the last 3 months Neurological or degenerative disease\n\n* Pregnant or breast-feeding\n* Adults under guardianship, curatorship or safeguard of justice\n* Cognitive impairment making it impossible to understand the protocol\n* Approach other than Moore posterolateral (for PTH and RTH groups)",{"count":207,"type":22},100,[25],"The study consists to evaluate the impact of prosthetic surgery (PTH and RTH) on kinematic and dynamic parameters (joint torques) of the lower limbs during gait initiation in patients with primary coxarthrosis.\n\nPatients included in the study will undergo a three-dimensional gait analysis. Dynamic gait analysis is multidimensional, measuring kinematic parameters (joint amplitudes: ankles, knees, hips, etc.) and dynamic parameters (assessment of joint torque from ankle, knee, hip to lower limb during gait initiation).",[211],"Primary; Coxarthrosis",[213,214,215,216],"Coxarthrosis","Hip","Arthroplasty","Gait initiation","2024-09-17",{"date":219,"type":41},"2024-09-19",{"date":221,"type":41},"2024-02-19",{"date":108,"type":22},{"name":47,"class":48},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":58,"minAge":89,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":110},"100553117","home-based-nurse-intervention-in-the-care-of-high-risk-of-death-patients-after-discharge-from-geriatric-department-100553117","NCT06481917","Home-based Nurse Intervention in the Care of High Risk of Death Patients After Discharge From Geriatric Department","Feasibility and Effectiveness of a Specialized Home-based Nurse Intervention on the Completion of Advance Care Plans of Patients at High Risk of Death After Discharge From Acute Care Geriatric Departement","SAPHARI","Inclusion Criteria:\n\n* Patients aged 75 or over.\n* Affiliated to a social security scheme.\n* Hospitalized in an acute care geriatric department\n* Discharged from hospital to home or residential facilities for dependent elderly people\n* Targeted pathology or at least one incurable disease.\n* At high risk of death in the twelve months following discharge according to the DAMAGE prognostic score (high-risk score group). A high risk of death is defined by a DAMAGE score \\> 50%.\n* Rockwood Clinical frailty scale score greater than or equal to 7 at one month.\n\nExclusion Criteria:\n\n* Refusal to participate in the study expressed by the patient or his\u002Fher legal representative, if applicable.\n* Patients transferred to another Medicine-Surgery-Obstetrics department (only \"medicine or surgery\" in the elderly).\n* Patients transferred to follow-up care and rehabilitation, palliative care, or returning home in palliative care.\n* Patients who have already drawn up advance directives, chosen a trusted support person or discussed their end-of-life wishes with their doctor.\n* Patients with proven severe neuro-cognitive disorders (in the medical record with a Mini-Mental State Examination (MMSE) score below 10 or in the absence of knowledge of the degree of severity and\u002For a recent previous MMSE score taken in a stable period, the referring practitioner, a geriatrician with expertise in this field, will assess whether the patient is unfit to state his or her advance directives at the time of inclusion.",{"count":233,"type":22},104,[25],"This study consists to evaluate the feasibility of a case-management intervention of Advance Care Plan (ACP) placement for elderly patients at high risk of death at twelve months discharged alive from acute geriatric medicine.\n\nFeasibility will include the following indicators: rate of patients included and randomized, rate of patients remaining in the study, ACP rates achieved at one month.",[237,238],"Health Services for the Aged","Advance Care Planning",[240,241,242,243,244],"Elderly","Advance care plan","DAMAGE score","High risk of mortality","Discharge from acute care geriatric department","2024-07-01",{"date":247,"type":41},"2024-07-03",{"date":249,"type":22},"2024-10",{"date":251,"type":22},"2027-10",{"name":47,"class":48},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":261,"targetDuration":263,"studyType":92,"phases":4,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":168},"100359588","prognostic-impact-of-imaging-parameters-in-patients-with-primary-mitral-insufficiency-by-prolapse-cohorte-im-100359588","NCT03962023","Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)","Prognostic Impact of Non-invasive Imaging Parameters (Cardiac Echocardiography and MRI) in Patients With Primary Mitral Insufficiency (MI) by Prolapse: Observational Cohort, Monocentric (COHORTE-IM)","COHORTE-IM","Inclusion Criteria:\n\n* Any patient with primary mitral insufficiency by prolapse (any grade) diagnosed by Trans-Thoracic Echocardiography (TTE)\n* From November 2010 to April 2019 (retrospective cohort)\n* From May 2019 to May 2024 (prospective cohort)\n* No previous surgery of the mitral valve before the first ultrasound\n* Adults\n* Patient who has been informed and not opposed to the use of his or her medical record data\n\nExclusion Criteria:\n\n* Secondary MI\n* Primary MI without valve prolapse\n* Active endocarditis\n* Patient's refusal to participate in the study\n* Patient under guardianship or curatorship",{"count":262,"type":22},400,"10 Years","Degenerative mitral insufficiency secondary to valve prolapse is the most common valve disease in Western countries. In the absence of specific treatment, it spontaneously progresses to heart failure and death when it is severe. Surgical mitral valve repair (or mitral plastic surgery) is the preferred treatment for primary mitral insufficiency by prolapse in case of severe leakage if associated with clinical and\u002For echocardiographic markers of poor prognosis (i.e., with high risk of morbi-mortality during their follow-up).\n\nIt is therefore essential to refine the risk stratification of these patients in order to identify at-risk patients who should potentially benefit earlier from invasive care (cardiac surgery), or conversely, close monitoring.\n\nA number of echocardiographic and MRI parameters may have been associated with a poorer prognosis.\n\nA cohort of patients with primary mitral insufficiency (MI) will be followed to study the relationships of a set of factors to patient prognosis.",[266],"Mitral Valve Insufficiency",[266,268,269],"Imagery","Prognosis","2024-03-25",{"date":272,"type":41},"2024-03-26",{"date":274,"type":41},"2019-09-04",{"date":276,"type":22},"2034-09",{"name":47,"class":48},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":88,"sex":58,"minAge":59,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":304},"100525068","hodgkins-disease-and-chemotherapy-before-40-years-100525068","NCT06116929","Hodgkin's Disease and Chemotherapy Before 40 Years","Functional and Cognitive Assessment of Patients With Hodgkin's Disease Undergoing Chemotherapy Before 40 Years","FunC-AHOD","Inclusion criteria - case :\n\n* Patient with newly diagnosed Hodgkin's disease\n* With intention to treat with chemotherapy +\u002F- radiotherapy\n* Aged between 18 and 40 years\n* Fluency in French\n* Able to undergo neuropsychological evaluation (absence of major sensory disorders)\n* Agreeing to take part in the study and having signed the informed consent form\n* Affiliated with a social security scheme\n\nInclusion criteria - controls:\n\n* Individual without Hodgkin's disease\n* Aged between 18 and 40\n* Proficient in French\n* Agreeing to participate in the study and having signed the informed consent form\n* Affiliated with a social security scheme\n\nCases and controls will be matched on age (± 5 years difference), and number of years of education (difference ≤ 2 years).\n\nNon-inclusion criteria - cases + controls :\n\n* Claustrophobia preventing MRI from being performed\n* Contraindication to MRI\n* Previous chemotherapy\n* History of neurological or psychiatric illness, including severe depression, or cognitive impairment\n* Use of medications that may cause neurological or psychiatric signs\n* Alcohol or drug abuse\n* Pregnant women\n* Persons under guardianship or trusteeship","40 Years",{"count":288,"type":22},63,[25],"A few studies have focused on other solid cancers (colorectal, prostate). On the other hand, the study of cognitive impairment in Hodgkin's disease remains less developed, and structural and functional post-therapy MRI studies have never been carried out. The impact of cognitive impairment on Hodgkin's disease is rarely, if ever, assessed in routine clinical practice, despite the fact that it is truly disabling in 16 to 30% of patients. Cognitive impairment can persist long after diagnosis and treatment. A recent study examining cognitive functioning in patients an average of 13 years after treatment found that disorders persisted in 52% of cases, with attentional, working memory and dysexecutive (planning) difficulties. These disorders have a significant impact on the daily and professional lives of these young, often working patients. Their rapid development and persistence after treatment can therefore represent a real limiting factor, impacting both professional integration and quality of life. Finally, the current state of knowledge does not allow us to dissociate cognitive disorders from emotional disorders and fatigue, which represent a major patient complaint. A better definition of the nature, pathophysiology and specificity of these disorders would therefore enable us to take better account of their repercussions (social, professional and on quality of life) and provide better care (in terms of cognitive remediation or psychological support).\n\nA prospective, longitudinal, multicenter, case-control interventional study in which cases are patients with Hodgkin's disease (HD) treated with CT +\u002F- radiotherapy and controls are healthy participants will be conducted. The aim is to study the prevalence and nature of treatment-induced cognitive impairment and its correlation with emotional comorbidities, as well as structural and functional brain disorders on MRI. The patient will thus be his or her own witness, the reference state being that at the time of diagnosis, before any treatment. The fact that this state has not already been altered by the disease itself, will be verify thanks to comparison with controls.",[292],"Hodgkin Disease",[292,294,295],"Chemotherapy","Functional and Cognitive Assessment","2024-02-26",{"date":298,"type":41},"2024-02-28",{"date":300,"type":22},"2024-05-15",{"date":302,"type":22},"2028-01-01",{"name":47,"class":48},4,{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":88,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":49},"100455250","study-of-the-immunomodulation-in-the-hidradenitis-suppurativa-and-evaluation-of-a-new-therapeutic-strategy-100455250","NCT05208099","Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy","Study of the Immunomodulation of the Immune Response in Hidradenitis Suppurativa and in Vitro and ex Vivo Evaluation of a New Therapeutic Strategy (IMOHS)","IMOHS","Inclusion criteria for HS patients :\n\n* Adult patients (≥18 years)\n* Carrier of moderate to severe (Hurley grade ≥2) hidradenitis suppurativa of classical or gluteal phenotype\n* Having an indication for surgical treatment (indication for excision)\n* Not receiving immunomodulatory treatments (corticotherapy, biotherapy, apremilast, retinoids) or immunosuppressive treatments (methotrexate, ciclosporin) in the 6 months before inclusion, excluding antibiotics\n* Agreement to participate\n* Affiliated to social security\n\nInclusion criteria for control receiving abdominoplasty :\n\n* Adult patients (≥18 years)\n* With no history of hidradenitis suppurativa or lesions suggestive of hidradenitis suppurativa (recurrent fold abscesses, recurrent fold suppuration, repeated draining in fold areas)\n* With an indication for abdominoplasty surgery\n* Not receiving immunomodulatory treatments (corticotherapy, biotherapy, apremilast, retinoids) or immunosuppressive treatments (methotrexate, ciclosporin) in the 6 months preceding inclusion, excluding antibiotics\n* Agreement to participate\n* Affiliated to social security\n\nCriteria for non-inclusion of patients with HS :\n\n* Immunosuppression, autoimmune disease(s), cancerous disease, or acute or chronic infectious disease\n* Difficulty understanding or reading French\n* Patients already included in a therapeutic interventional trial\n* Patients under guardianship or curatorship\n* Pregnant or breast feeding women\n* Syndromic hidradenitis suppurativa, hidradenitis suppurativa of follicular phenotype\n\nCriteria for non-inclusion of controls receiving abdominoplasty :\n\n* Immunosuppression, autoimmune disease(s), cancerous disease, or acute or chronic infectious disease\n* Difficulty understanding or reading french\n* Patients already included in a therapeutic interventional trial\n* Patients under guardianship or curatorship\n* Pregnant or breastfeeding women",{"count":314,"type":22},20,"Hidradenitis suppurativa (HS), also known as Verneuil's disease, is a chronic inflammatory dermatosis of the hair follicule located mainly in the skin folds (axillae, inguinal, submammary, etc.).\n\nCurrently, treatments are mainly limited to the use of broad-spectrum antibiotics in order to control outbreaks of hidradenitis suppurativa. Surgical treatment is the only curative treatment, but requires disfiguring removals with major scarring consequences.\n\nPathophysiologically, HS appears to be a primary abnormality of the pilosebaceous-apocrine unit, causing follicular occlusion, followed by the development of perifollicular cysts with commensal bacterial overgrowth, and finally rupture into the dermis causing an exaggerated inflammatory response. At present, few studies have examined the role of the regulatory immune system and its involvement in this disease.\n\nWe are also interested in analyzing the impact of new therapeutic strategies on hidradenitis suppurativa, and more particularly the impact of photodynamic therapy (PDT) which is a technique that has been used for a long time in dermatology, notably for the treatment of precancerous and cancerous lesions.\n\nThis technique has shown interesting results on inflammatory dermatoses such as acne.\n\nThis research consists in studying the immunomodulation of the immune response in HS and in evaluating a new therapeutic strategy based on PDT alone or in combination with antimicrobial peptides (PAMs).",[317],"Hidradenitis Suppurativa",[319,320,321,322,323,324],"Hidradenitis suppurativa","inflammatory nodules","abscesses","fistulas","scars","surgery","2023-10-30",{"date":327,"type":41},"2023-10-31",{"date":329,"type":22},"2024-01-01",{"date":331,"type":22},"2026-06-30",{"name":47,"class":48},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":341,"targetDuration":263,"studyType":92,"phases":4,"briefSummary":342,"conditions":343,"keywords":347,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":168},"100415852","crystalille-cohort-getting-the-whole-picture-of-crystal-related-arthropathies-100415852","NCT04695028","CRYSTALILLE Cohort: Getting the Whole Picture of Crystal-related Arthropathies","Data Collection for the Constitution of an Observatory for Patients Suffering From Microcrystalline Rheumatism With Morphological Phenotyping","CRYSTALILLE","Inclusion Criteria:\n\n* Diagnosis of gout according to American College of Rheumatology \u002FEuropean League Against Rheumatism (ACR\u002FEULAR) 2015 criteria OR diagnosis of calcium pyrophosphate dihydrate crystal deposition disease (CPPD) based on EULAR 2011 recommendations OR diagnosis of hydroxyapatite crystal rheumatism (HCR) according to a typical clinical sequence and demonstration of compatible calcium deposits on imaging\n* patient who will benefit or has benefited from an ultrasound and\u002For DECT evaluation of microcrystalline deposits\n* clinical suspicion of microcrystalline rheumatism requiring further imaging to confirm the diagnosis\n\nExclusion Criteria:\n\n* Refusal or contra-indication to perform ultrasound or dual energy scanning.\n* Patient's opposition to the use of his or her health data for research purposes\n* Patient under guardianship or curatorship\n* Pregnant woman\n* Person not affiliated to a social security scheme or entitled to a social security benefit",{"count":179,"type":22},"The objective of this research is to collect data to create an observatory of microcrystalline rheumatism (gout and calcium-crystal rheumatism) in patients treated at the Groupement des Hôpitaux de l'Institut Catholique de Lille, in order to better understand the disease and improve patient care, in particular with the help of medical imaging.",[344,345,346],"Gout","Chondrocalcinosis","Hydroxyapatite",[344,345,346],"2023-06-21",{"date":350,"type":41},"2023-06-23",{"date":352,"type":41},"2021-03-16",{"date":354,"type":22},"2030-10",{"name":47,"class":48},""]